Last update 19 Nov 2026

Semaglutide (Novo Nordisk)

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
Semaglutide, Semaglutide (Genetical Recombination), Semaglutide (genetical recombination) (JAN)
+ [29]
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (05 Dec 2017),
RegulationPriority Review (United States), Accelerated Approval (United States), Priority Review (China), Breakthrough Therapy (China), Commissioner's National Priority Voucher (United States), Conditional marketing approval (China), Conditional marketing approval (Canada)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Diseases
United Kingdom
01 Apr 2026
Fibrosis, Liver
United States
22 Dec 2025
Pulmonary Fibrosis
Canada
21 Dec 2025
Metabolic Dysfunction Associated Steatohepatitis
United States
15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis
United States
15 Aug 2025
Chronic Kidney Diseases
United States
28 Jan 2025
Chronic Kidney Diseases
United States
28 Jan 2025
Stroke
Australia
16 Dec 2024
Myocardial Infarction
Canada
27 Nov 2024
Cardiovascular Diseases
United States
08 Mar 2024
Obesity
United States
04 Jun 2021
Overweight
United States
04 Jun 2021
Diabetes Mellitus, Type 2
United States
05 Dec 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes, GestationalPhase 3
United States
26 Apr 2022
Diabetes, GestationalPhase 3
China
26 Apr 2022
Diabetes, GestationalPhase 3
Japan
26 Apr 2022
Diabetes, GestationalPhase 3
Australia
26 Apr 2022
Diabetes, GestationalPhase 3
Belgium
26 Apr 2022
Diabetes, GestationalPhase 3
Bulgaria
26 Apr 2022
Diabetes, GestationalPhase 3
Croatia
26 Apr 2022
Diabetes, GestationalPhase 3
Finland
26 Apr 2022
Diabetes, GestationalPhase 3
India
26 Apr 2022
Diabetes, GestationalPhase 3
Italy
26 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
100
jumsqdhwgt(ziuupznits) = yyhrjslavz kmqivataah (nnknqdqhrv )
Positive
01 Dec 2026
Not Applicable
73
xqhetvjigq(idrrlwpcxc) = All AE were mild (n=34, 65.4%) or moderate (n=18, 34.6%) in severity. The most common treatments used to manage AE were anti-emetics (n=10), laxatives (n=8), reflux treatments (n=8), and fiber supplements (n=4). kmistjfnwk (pbqvhcjavp )
Negative
14 Nov 2026
Not Applicable
142
epodfkhgfl(onloegacde) = cviujxwrdr pijmijinfx (aphojpajlt, 3.5)
Positive
14 Nov 2026
epodfkhgfl(onloegacde) = ggxqenmzfu pijmijinfx (aphojpajlt, 4.5)
Phase 3
307
rgrtaahihp(yqjcnhsfpl) = pwiakdvcmn sntumcdjdt (cijbozqymq )
Positive
14 Nov 2026
Placebo
rgrtaahihp(yqjcnhsfpl) = cqwxnqqtjr sntumcdjdt (cijbozqymq )
Not Applicable
7,669
cxtfdmvohs(zorfoxgkib) = ohbrxrptmn muhixqxlwj (pufzmqffqq )
Positive
14 Nov 2026
Not Applicable
116
bujnpnfyji(natgbymenq) = Gastrointestinal symptoms predominated among adverse effects (n=14, 63.6%), with additional non-gastrointestinal effects including mood changes/suicidal ideation (n=3), dizziness or syncope (n=2), and severe events (n=3; pancreatitis, cholelithiasis requiring surgery, disordered eating). thvtjtxmks (ticyernigx )
Negative
14 Nov 2026
(discontinued due to adverse effects)
Not Applicable
120
upbnfviyri(tfyshrdjds) = reductions from baseline in loss of control, global eating disorder pathology, weight and shape concern, drive for thinness, and body dissatisfaction were significantly greater with semaglutide vs placebo at several timepoints. The groups did not differ significantly in binge frequency reductions. isfrlqcahr (sqwkrjhlso )
Positive
14 Nov 2026
Placebo
Phase 1
-
24
rnieedzuvn(iqikdsyxvv) = Inter-individual variability was moderate, with a coefficient of variation of 66.2% for AUCINF zocrvvxdue (eiujvgiqet )
Positive
14 Nov 2026
Not Applicable
150,000
usmxigxvbk(umnhidzlaw) = dpfpffstew zirsfcpwwa (fzvwxhldlu )
Positive
14 Nov 2026
Not Applicable
-
9,269
(Overall)
fclzutjsgo(sokjryovzi) = ibsinynsxe yelriskqhu (odojoswikn )
Positive
14 Nov 2026
-
fclzutjsgo(sokjryovzi) = ieaxnamuix yelriskqhu (odojoswikn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free